Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 206

1.

Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.

Carlo MI, Giri VN, Paller CJ, Abida W, Alumkal JJ, Beer TM, Beltran H, George DJ, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Ryan CJ, Schaeffer EM, Stadler WM, Taplin ME, Kauff ND, Vinson J, Antonarakis ES, Cheng HH.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00060. Epub 2018 Aug 16.

PMID:
30761386
2.

A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.

McHugh D, Eisenberger M, Heath EI, Bruce J, Danila DC, Rathkopf DE, Feldman J, Slovin SF, Anand B, Chu R, Lackey J, Reyno L, Antonarakis ES, Morris MJ.

Invest New Drugs. 2019 Feb 6. doi: 10.1007/s10637-019-00731-5. [Epub ahead of print]

PMID:
30725389
3.

A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer.

Antonarakis ES.

Oncologist. 2019 Jan 9. pii: theoncologist.2018-0819. doi: 10.1634/theoncologist.2018-0819. [Epub ahead of print] No abstract available.

PMID:
30626711
4.

Favorable Response to Pembrolizumab in a Patient With Metastatic Castration-Resistant Prostate Cancer Progressing While Receiving Enzalutamide.

Dib EG, Antonarakis ES, Wasco MJ, Powell SF.

Clin Genitourin Cancer. 2018 Dec 6. pii: S1558-7673(18)30780-8. doi: 10.1016/j.clgc.2018.11.021. [Epub ahead of print] No abstract available.

PMID:
30587403
5.

Targeting ELK1: a wELKome addition to the prostate cancer armamentarium.

Zarif JC, Antonarakis ES.

AME Med J. 2018 Oct;3. pii: 104. doi: 10.21037/amj.2018.10.08. Epub 2018 Oct 31. No abstract available.

6.

Selective inhibitors of nuclear export: potential therapeutics for AR variant-expressing prostate cancer.

Antonarakis ES.

Oncotarget. 2018 Nov 9;9(88):35797-35798. doi: 10.18632/oncotarget.26296. eCollection 2018 Nov 9. No abstract available.

7.

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.

Basch EM, Scholz M, de Bono JS, Vogelzang N, de Souza P, Marx G, Vaishampayan U, George S, Schwarz JK, Antonarakis ES, O'Sullivan JM, Kalebasty AR, Chi KN, Dreicer R, Hutson TE, Dueck AC, Bennett AV, Dayan E, Mangeshkar M, Holland J, Weitzman AL, Scher HI.

Eur Urol. 2018 Dec 4. pii: S0302-2838(18)30932-1. doi: 10.1016/j.eururo.2018.11.033. [Epub ahead of print]

8.

PARP inhibition - not all gene mutations are created equal.

Luo J, Antonarakis ES.

Nat Rev Urol. 2019 Jan;16(1):4-6. doi: 10.1038/s41585-018-0129-3. No abstract available.

PMID:
30498248
9.

AR-V7 and treatment selection in advanced prostate cancer: are we there yet?

Bastos DA, Antonarakis ES.

Precis Cancer Med. 2018 Sep;1. pii: 13. doi: 10.21037/pcm.2018.09.01. Epub 2018 Sep 18. No abstract available.

10.

Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations.

Antonarakis ES, Shaukat F, Isaacsson Velho P, Kaur H, Shenderov E, Pardoll DM, Lotan TL.

Eur Urol. 2019 Mar;75(3):378-382. doi: 10.1016/j.eururo.2018.10.009. Epub 2018 Oct 15.

PMID:
30337059
11.

Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY.

Tagawa ST, Antonarakis ES, Gjyrezi A, Galletti G, Kim S, Worroll D, Stewart J, Zaher A, Szatrowski TP, Ballman KV, Kita K, Tasaki S, Bai Y, Portella L, Kirby BJ, Saad F, Eisenberger MA, Nanus DM, Giannakakou P.

Clin Cancer Res. 2018 Oct 9. pii: clincanres.0320.2018. doi: 10.1158/1078-0432.CCR-18-0320. [Epub ahead of print]

PMID:
30301829
12.

Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.

Isaacsson Velho P, Qazi F, Hassan S, Carducci MA, Denmeade SR, Markowski MC, Thorek DL, DeWeese TL, Song DY, Tran PT, Eisenberger MA, Antonarakis ES.

Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30729-2. doi: 10.1016/j.eururo.2018.09.040. [Epub ahead of print]

PMID:
30293905
13.

Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer.

Antonarakis ES.

N Engl J Med. 2018 Sep 13;379(11):1087-1089. doi: 10.1056/NEJMcibr1808772. No abstract available.

PMID:
30207914
14.

Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.

Moyer CL, Phillips R, Deek MP, Radwan N, Ross AE, Antonarakis ES, Reyes D, Wright J, Terezakis SA, Song DY, DeVille C, Walsh PC, DeWeese TL, Carducci M, Schaeffer EM, Pienta KJ, Eisenberger M, Tran PT.

World J Urol. 2018 Sep 6. doi: 10.1007/s00345-018-2477-2. [Epub ahead of print]

PMID:
30191396
15.

Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage.

Marshall CH, Fu W, Wang H, Baras AS, Lotan TL, Antonarakis ES.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):59-65. doi: 10.1038/s41391-018-0086-1. Epub 2018 Aug 31.

PMID:
30171229
16.

Detection of AR-V7 transcript with RNA in situ hybridization in human salivary duct cancer.

Kang H, Antonarakis ES, Luo J, Zheng Q, Rooper L, De Marzo AM, Westra WH, Lotan TL.

Oral Oncol. 2018 Sep;84:134-136. doi: 10.1016/j.oraloncology.2018.06.026. Epub 2018 Jun 28. No abstract available.

PMID:
30122219
17.

Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies.

Sfanos KS, Markowski MC, Peiffer LB, Ernst SE, White JR, Pienta KJ, Antonarakis ES, Ross AE.

Prostate Cancer Prostatic Dis. 2018 Nov;21(4):539-548. doi: 10.1038/s41391-018-0061-x. Epub 2018 Jul 9.

18.

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.

Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H, Niknafs N, White JR, Silberstein JL, Sullivan R, Dowling D, Harb R, Nirschl TR, Veeneman BA, Tomlins SA, Wang Y, Jendrisak A, Graf RP, Dittamore R, Carducci MA, Eisenberger MA, Haffner MC, Meeker AK, Eshleman JR, Luo J, Velculescu VE, Drake CG, Antonarakis ES.

Oncotarget. 2018 Jun 19;9(47):28561-28571. doi: 10.18632/oncotarget.25564. eCollection 2018 Jun 19.

19.

Reply to C. Ren et al.

Antonarakis ES.

J Clin Oncol. 2018 Aug 1;36(22):2356-2357. doi: 10.1200/JCO.2018.78.2680. Epub 2018 Jun 12. No abstract available.

PMID:
29894276
20.

Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?

Antonarakis ES.

Lancet Oncol. 2018 Jul;19(7):860-861. doi: 10.1016/S1470-2045(18)30409-1. Epub 2018 Jun 4. No abstract available.

PMID:
29880290
21.

Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival.

Antonarakis ES, Small EJ, Petrylak DP, Quinn DI, Kibel AS, Chang NN, Dearstyne E, Harmon M, Campogan D, Haynes H, Vu T, Sheikh NA, Drake CG.

Clin Cancer Res. 2018 Oct 1;24(19):4662-4671. doi: 10.1158/1078-0432.CCR-18-0638. Epub 2018 Jun 1.

PMID:
29858218
22.

Germline genetic testing in prostate cancer - further enrichment in variant histologies?

Markowski MC, Antonarakis ES.

Oncoscience. 2018 Apr 29;5(3-4):62-64. doi: 10.18632/oncoscience.403. eCollection 2018 Mar. No abstract available.

23.

Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.

Chen Z, Wu D, Thomas-Ahner JM, Lu C, Zhao P, Zhang Q, Geraghty C, Yan PS, Hankey W, Sunkel B, Cheng X, Antonarakis ES, Wang QE, Liu Z, Huang TH, Jin VX, Clinton SK, Luo J, Huang J, Wang Q.

Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):6810-6815. doi: 10.1073/pnas.1718811115. Epub 2018 May 29. Erratum in: Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E9025.

24.

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.

Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16. Review.

PMID:
29673712
25.

Microsatellite instability in prostate cancer by PCR or next-generation sequencing.

Hempelmann JA, Lockwood CM, Konnick EQ, Schweizer MT, Antonarakis ES, Lotan TL, Montgomery B, Nelson PS, Klemfuss N, Salipante SJ, Pritchard CC.

J Immunother Cancer. 2018 Apr 17;6(1):29. doi: 10.1186/s40425-018-0341-y.

26.

PD-1/PD-L1 pathway inhibitors in advanced prostate cancer.

Isaacsson Velho P, Antonarakis ES.

Expert Rev Clin Pharmacol. 2018 May;11(5):475-486. doi: 10.1080/17512433.2018.1464388. Epub 2018 Apr 24. Review.

PMID:
29641940
27.

Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors.

Jacobs MA, Macura KJ, Zaheer A, Antonarakis ES, Stearns V, Wolff AC, Feiweier T, Kamel IR, Wahl RL, Pan L.

Acad Radiol. 2018 Nov;25(11):1405-1414. doi: 10.1016/j.acra.2018.02.010. Epub 2018 Apr 4.

28.

PARP inhibitors for homologous recombination-deficient prostate cancer.

Christenson ES, Antonarakis ES.

Expert Opin Emerg Drugs. 2018 Jun;23(2):123-133. doi: 10.1080/14728214.2018.1459563. Epub 2018 Apr 4. Review.

29.

Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer.

Haffner MC, Guner G, Taheri D, Netto GJ, Palsgrove DN, Zheng Q, Guedes LB, Kim K, Tsai H, Esopi DM, Lotan TL, Sharma R, Meeker AK, Chinnaiyan AM, Nelson WG, Yegnasubramanian S, Luo J, Mehra R, Antonarakis ES, Drake CG, De Marzo AM.

Am J Pathol. 2018 Jun;188(6):1478-1485. doi: 10.1016/j.ajpath.2018.02.014. Epub 2018 Mar 22.

PMID:
29577933
30.

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation.

Shenderov E, Gorin MA, Kim S, Johnson PT, Allaf ME, Partin AW, Pomper MG, Antonarakis ES, Pienta KJ, Rowe SP.

Urol Case Rep. 2017 Dec 19;17:22-25. doi: 10.1016/j.eucr.2017.12.011. eCollection 2018 Mar.

31.

Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.

Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y, Silberstein JL, Piana D, Lai Z, Chen Y, Isaacs WB, Luo J.

Eur Urol. 2018 Aug;74(2):218-225. doi: 10.1016/j.eururo.2018.01.035. Epub 2018 Feb 10.

PMID:
29439820
32.

Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.

Isaacsson Velho P, Silberstein JL, Markowski MC, Luo J, Lotan TL, Isaacs WB, Antonarakis ES.

Prostate. 2018 Apr;78(5):401-407. doi: 10.1002/pros.23484. Epub 2018 Jan 25.

PMID:
29368341
33.

Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis.

Fang M, Nakazawa M, Antonarakis ES, Li C.

Prostate Cancer. 2017;2017:8560827. doi: 10.1155/2017/8560827. Epub 2017 Nov 21.

34.

AR Signaling in Human Malignancies: Prostate Cancer and Beyond.

Antonarakis ES.

Cancers (Basel). 2018 Jan 18;10(1). pii: E22. doi: 10.3390/cancers10010022.

35.

CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.

Bastos DA, Antonarakis ES.

Expert Rev Mol Diagn. 2018 Feb;18(2):155-163. doi: 10.1080/14737159.2018.1427068. Epub 2018 Jan 16. Review.

36.

p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer.

Maughan BL, Guedes LB, Boucher K, Rajoria G, Liu Z, Klimek S, Zoino R, Antonarakis ES, Lotan TL.

Prostate Cancer Prostatic Dis. 2018 Jun;21(2):260-268. doi: 10.1038/s41391-017-0027-4. Epub 2018 Jan 4.

PMID:
29302046
37.

Surrogate end points in early prostate cancer clinical states: ready for implementation?

Kyriakopoulos CE, Antonarakis ES.

Ann Transl Med. 2017 Dec;5(24):502. doi: 10.21037/atm.2017.10.25. No abstract available.

38.

Circulating Tumor Cell Eradication as an Intermediate Efficacy End Point for Metastatic Castration-Resistant Prostate Cancer: Is There Enough Evidence?

Antonarakis ES.

J Clin Oncol. 2018 Feb 20;36(6):525-527. doi: 10.1200/JCO.2017.76.5487. Epub 2017 Dec 22. No abstract available.

PMID:
29272163
39.

The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.

McNamara M, Sweeney C, Antonarakis ES, Armstrong AJ.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):306-318. doi: 10.1038/s41391-017-0014-9. Epub 2017 Dec 20. Review.

PMID:
29263421
40.

Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy.

Ross AE, Hughes RM, Glavaris S, Ghabili K, He P, Anders NM, Harb R, Tosoian JJ, Marchionni L, Schaeffer EM, Partin AW, Allaf ME, Bivalacqua TJ, Chapman C, O'Neal T, DeMarzo AM, Hurley PJ, Rudek MA, Antonarakis ES.

Oncotarget. 2017 Oct 26;8(61):104182-104192. doi: 10.18632/oncotarget.22115. eCollection 2017 Nov 28.

41.

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.

Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, Cao X, Tomlins SA, Mehra R, Cooney KA, Montgomery B, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, Smith DC, Caram MV, Knudsen KE, Stadler WM, Feng FY, Chinnaiyan AM.

J Clin Oncol. 2018 Apr 1;36(10):991-999. doi: 10.1200/JCO.2017.75.7310. Epub 2017 Dec 20.

42.

Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.

Handy CE, Antonarakis ES.

Future Oncol. 2018 Apr;14(10):907-917. doi: 10.2217/fon-2017-0531. Epub 2017 Dec 20. Review.

PMID:
29260582
43.

Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, Spitz A, DeCarli M, Sinibaldi V, Pratz CF, Lu C, Silberstein JL, Luo J, Schweizer MT, Drake CG, Carducci MA, Paller CJ, Antonarakis ES, Eisenberger MA, Denmeade SR.

Lancet Oncol. 2018 Jan;19(1):76-86. doi: 10.1016/S1470-2045(17)30906-3. Epub 2017 Dec 14.

44.

Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer.

Markowski MC, Silberstein JL, Eshleman JR, Eisenberger MA, Luo J, Antonarakis ES.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00127. Epub 2017 Oct 30.

45.

Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.

Paller CJ, Zhou XC, Heath EI, Taplin ME, Mayer T, Stein MN, Bubley GJ, Pili R, Hudson T, Kakarla R, Abbas MM, Anders NM, Dowling D, King S, Bruns AB, Wagner WD, Drake CG, Antonarakis ES, Eisenberger MA, Denmeade SR, Rudek MA, Rosner GL, Carducci MA.

Clin Cancer Res. 2018 Jan 15;24(2):306-315. doi: 10.1158/1078-0432.CCR-17-1100. Epub 2017 Nov 7.

46.

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.

Armstrong AJ, Antonarakis ES, Taplin ME, Kelly WK, Beltran H, Fizazi K, Dahut WL, Shore N, Slovin S, George D, Carducci MA, Corn P, Danila D, Dreicer R, Heath E, Rathkopf D, Liu G, Nanus D, Stein M, Smith MR, Sternberg C, Wilding G, Nelson PS, Halabi S, Kantoff P, Clarke NW, Evans CP, Heidenreich A, Mottet N, Gleave M, Morris MJ, Scher HI.

Ann Oncol. 2018 Jan 1;29(1):23-25. doi: 10.1093/annonc/mdx648. No abstract available.

47.

Prognostic and therapeutic implications of DNA repair gene mutations in advanced prostate cancer.

Schweizer MT, Antonarakis ES.

Clin Adv Hematol Oncol. 2017 Oct;15(10):785-795. Review.

PMID:
29040258
48.

BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations.

Markowski MC, De Marzo AM, Antonarakis ES.

Expert Opin Investig Drugs. 2017 Dec;26(12):1391-1397. doi: 10.1080/13543784.2017.1393518. Epub 2017 Oct 27. Review.

PMID:
29032717
49.

Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.

Zhu Y, Sharp A, Anderson CM, Silberstein JL, Taylor M, Lu C, Zhao P, De Marzo AM, Antonarakis ES, Wang M, Wu X, Luo Y, Su N, Nava Rodrigues D, Figueiredo I, Welti J, Park E, Ma XJ, Coleman I, Morrissey C, Plymate SR, Nelson PS, de Bono JS, Luo J.

Eur Urol. 2018 May;73(5):727-735. doi: 10.1016/j.eururo.2017.08.009. Epub 2017 Sep 1.

PMID:
28866255
50.

Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications.

Terada N, Akamatsu S, Kobayashi T, Inoue T, Ogawa O, Antonarakis ES.

Ther Adv Med Oncol. 2017 Aug;9(8):565-573. doi: 10.1177/1758834017719215. Epub 2017 Jul 5. Review.

Supplemental Content

Loading ...
Support Center